Data Analysis of Adult and Pediatric Participants With Acid Sphingomyelinase Deficiency (ASMD) on Early Access to Olipudase Alfa in France

Inclusion Criteria: * The patient, or the patient's parent(s)/guardian(s), has signed written informed consent. * Patients with a confirmed diagnosis of ASMD under early access to olipudase alfa in France (ie, nominative compassionate use, pre marketing authorization early access, post marketing authorization early access). * The patient has documented deficiency of acid sphingomyelinase in peripheral leukocytes, lymphocytes, or cultured fibroblasts. * Male and female patients of all ages. Exclusion Criteria: * The patient or legal guardian(s) who has not received information notice or who opposes to data collection. * Patient who died before study initiation and who was opposed to data collection for research purpose when he/she was alive. The above information is not intended to contain all considerations relevant to a potential participation in a clinical trial.